Lawsuit Help Desk

Elmiron Lawsuits and Settlements

Have you been diagnosed with interstitial cystitis and prescribed Elmiron? Did you take the medication for a minimum of three months?  After taking the drug, have you had any vision loss or other vision problems, or were you diagnosed with Pigmentary Maculopathy?

If yes, there is a high chance that you would qualify for an Elmiron lawsuit and settlement opportunity. Talk to our leading Elmiron lawsuit attorneys now!

Will your leading mass torts
firms take my case?

Contact us to find out (We’ll get back to you the same day)

"*" indicates required fields

I represent, understand and agree that: 1) I am 18 years of age or older; 2) I have read and agree to’s Terms of Service, Privacy Policy, that the representations here are Paid Attorney Advertising, and additional legal disclaimers herein (if any); 3) submitting this form does not create an attorney-client relationship; 4) I am not already represented by an attorney for this matter; and 5) I consent to be contacted under the Terms and Conditions of Contact in order to discuss my legal options, so that I may obtain legal representation.

What are the ElMiron Lawsuits?

Elmiron Eye Lawsuit

Millions of Americans use the prescription drug Elmiron (pentosan polysulfate sodium) to treat chronic bladder inflammation and diseases that are associated with it. Nevertheless, in 2018, a novel type of retinal injury was identified by medical professionals at the Emory Eye Center in Atlanta, Georgia. Six of the patients exhibited abnormal damage to the macula region of their eyes and were identified as having pigmentary maculopathy, which is thought to be brought on by long-term drug use and result in blindness and visual loss. Lawyers accuse the maker of Elmiron, Janssen Pharmaceuticals Inc., for having failed to adequately warn consumers and the medical community about vision damage associated with long-term use of the medication. 


Individuals who have taken Elmiron, a drug prescribed to treat interstitial cystitis, have filed lawsuits claiming that they have suffered injuries as a result. Pentosan polysulfate sodium, marketed under the brand name Elmiron, has also become one of Janssen’s best-selling drugs which mostly affects women. Elmiron is the sole FDA-approved drug for IC treatment and was developed by Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson, and has been in use since its approval in 1996. 

Most recent development

As a result of this revelation, more than 900 lawsuits have been filed in federal court by individuals who have experienced vision loss or damage as a result of taking Elmiron. These lawsuits have been consolidated into a class-action MDL in New Jersey, and the first bellwether test trials for the Elmiron MDL are scheduled to begin in January 2023.

Elmiron is widely used by millions of people to manage chronic bladder conditions, and it’s often the first choice for individuals with interstitial cystitis (IC). The drug is typically considered safe with minimal side effects, and Janssen, its manufacturer, has enjoyed tremendous sales success.

Long-term use of Elmiron

However, concerns have been raised about the long-term use of Elmiron at high doses by a research team led by Dr. Victoria S. Pelak from the University of Colorado School of Medicine’s Department of Ophthalmology. Other researchers from prestigious institutions such as Johns Hopkins Medicine and Harvard Medical School are part of this study. The research focuses on analyzing the safety and effectiveness of Elmiron, a medication used to treat interstitial cystitis. The team has discovered that prolonged use of Elmiron at high doses can lead to severe retinal damage, potentially causing permanent vision impairment and even blindness. Subsequent research has confirmed the link between Elmiron and eye damage.

Vision loss

Medical professionals are advising individuals who have used Elmiron in the past to undergo an ophthalmic examination to detect maculopathy at an early stage, as early detection is critical for effective treatment. Maculopathy is a progressive disease that can result in central vision loss, impaired vision, and blindness. The specific type of macular degeneration linked to Elmiron is pigmentary maculopathy, which damages the macula at the back of the eye. Patients with this condition may experience various visual symptoms such as dimming of vision, distorted images, blurry or black spots in the center of vision, and legal blindness.

As a result, a significant number of lawsuits have been filed against Janssen, claiming that the company’s drug caused vision loss or damage. Over 1,740 individuals have filed Elmiron lawsuits in federal court, and many more have been filed in state courts, accusing the company of negligence and failure to warn about the drug’s risks.

2019 study

In July 2019, a significant study by Drs. Adam M. Hanif and Nieraj Jain on Elmiron and pigmentary maculopathy was published in the Review of Ophthalmology. The authors defined the eye damage resulting from the drug as “preventable pharmacological toxicity that threatens vision and could be erroneously diagnosed as other recognized maculopathies.” It wasn’t until much later after Elmiron’s launch that its use was found to be strongly associated with the onset of maculopathy, a devastating eye disease. This discovery has sparked concern among both medical professionals and patients who rely on Elmiron for interstitial cystitis treatment.

FDA warning

At this time, the U.S. Food and Drug Administration (FDA) has not issued a safety warning about Elmiron-related vision problems, but continues to investigate patients’ reports of vision damage linked to long-term use of the medication. 

Concerns about the drug’s side effects began to emerge in 2018 when six patients at the Emory Eye Center in Atlanta were diagnosed with pigmentary maculopathy and found to have abnormal damage to the macula region of their eyes. Further investigation revealed that all of these patients were long-term users of Elmiron. A preliminary report published by the Emory Eye Center suggested that the drug may be toxic to retinal tissue in the human eye.

The fact that Elmiron’s manufacturer has known about the long-term harm for more than 20 years despite the medical community only lately learning about the side effects is troubling. Patients who took Elmiron for three to four years noticed negative effects linked to their vision and eyes in early clinical trials.

2023 status update

As of February 20, 2023, the number of pending Elmiron vision loss cases in the class action MDL has increased by 31 in the past month, bringing the total to 1,872. The first bellwether test trial is scheduled to begin in three months, and there is speculation that Janssen may begin settling large blocks of these cases in the near future.

Discovery stage

The legal team representing the plaintiffs in the Elmiron eye damage litigation is currently in the discovery phase of the case, gathering evidence and information in preparation for trial. The first trial involving Elmiron is scheduled for March 2023.

In December 2020, a multidistrict litigation (MDL) was established for Elmiron in federal court in New Jersey. Your law firm is serving on the Executive Committee for the MDL and the chair of the Discovery Committee. 

The formation of an MDL is the initial phase in the legal process that commences settlement negotiations. Following the establishment of the MDL, fact-finding and trials can begin, which can eventually lead to serious settlement discussions.

No recall yet

Elmiron has not been recalled, but the lawsuits against the drug accuse that there should have been a warning label indicating the risk of macular eye damage associated with prolonged use of the medication at high doses. The studies have demonstrated a clear link between Elmiron use and macular eye damage, which calls for the need of a warning label. Despite the need for a warning label, Elmiron is still available for prescription to treat bladder conditions.

2017 Elmiron settlement

In 2017, Janssen Pharmaceuticals settled various lawsuits related to Elmiron, including personal injury and wrongful death claims, by agreeing to pay $27.5 million.

2019 Elmiron settlement

Another substantial settlement was made in 2019, where the company agreed to pay $25 million to resolve approximately 300 lawsuits related to Elmiron, which also included both personal injury and wrongful death cases.

It is likely that the Elmiron class action MDL will reach a final settlement either shortly before or shortly after the first trial in March 2023. In most cases involving defective drugs, global settlements typically take time, so it’s not advisable to believe a lawyer who promises a quick Elmiron settlement.

2023 Elmiron settlements

The Elmiron lawsuits are in a favorable position for settlement in 2023, as much of the pre-trial discovery is already completed. Therefore, this is a unique opportunity for individuals with Elmiron claims to file them now and receive a settlement quickly.

A final settlement in the Elmiron class action MDL will probably be resolved shortly before or shortly after the first trial in March 2023.

Ripe for settlement

Global settlements in most big defective drug cases take time. If a lawyer tells you she will get you a quick Elmiron settlement, you normally want to run the other way.  But… the Elmiron lawsuits are ripe for settlement in 2023, and the pre-trial discovery is mainly done.  So this is a unique moment where if you have an Elmiron claim and bring it now, there is a possibility of a settlement coming quickly.

Who can file an Elmiron lawsuit?

You may qualify to file an Elmiron lawsuit if you meet these criteria:

  • 3 months usage; and
  • Vision loss, or other vision issues, or diagnosis of Pigmentary Maculopathy
woman recovering in hospital who's filed an Elmiron lawsuit
weighing the benefits of Elmiron lawsuit

What are my legal fees, if your lawyers take my Elmiron case?

It is great news for you that if you meet the criteria, the legal representation will be entirely on a contingency fee basis. This implies that the law firm handling your case will cover all costs and expenses related to the legal proceedings, and you will not have to pay anything. Your legal fees will be paid out of the settlement or award you receive.

It’s worth noting that you will be represented by experts in the field, not just personal injury lawyers or individuals who are paying a marketing firm for leads, unlike most other mass tort websites.

In the unlikely scenario that the case is not settled or won, you will not be required to pay anything since the law firm representing you will assume all the risk.

How much can I recover from my Elmiron lawsuit?

Based on the experience of our leading mass torts lawyers, you may recover the following settlement amounts:

Vision Impairment LevelSettlement Range
80% – 100%$700,000 – $1,000,000
40% – 80%$370,000 – $700,000
20% – 40%$80,000 – $200,000
Under 20%$30,000 – $50,000
celebrating Elmiron Lawsuits settlement
lawyer counseling about Elmiron lawsuit

What happens if I qualify?

You have no obligations to us if you’re qualified. If we find that you are qualified, and you wish to proceed with the mass torts firms we have provided for you, the lawyers will discuss the retention agreement with you.

How much time do I have left to file my Elmiron lawsuit?

For your and your family’s sake, act quickly, even if it’s not with us. Why?

Statutes of limitations (SOL), worsened by lagging scientific research, may bar your recovery. Also, if you file late, you may miss important settlement opportunities.  That’s why it’s very important to secure legal representation as soon as possible.

Know that one of our lawyers’ first actions will be to check your state’s statute of limitations and repose. 

File your Elmiron lawsuit as soon as possible because your state’s statutes of limitations (SOL) and statutes of repose (SOR) limit your time to do so.

These statutes restrict the enforcement of claims after the expiration of a given time period. Therefore, in this case, you will no longer be able to recover.

Sadly, yes. You cannot recover as a plaintiff if you do not have a pending case.

This is why you need to consult with our leading mass torts lawyers now. They specialize in cases such as the Elmiron lawsuits. 

Do not miss your settlement opportunity.

Unfortunately, yes. This is why you need to file your Elmiron lawsuit as soon as possible.

Scientifically-established proof requires time. Hence, any evidence from the manufacturer will require a substantial amount of research and scientific inquiry. 

With the current scientific basis for the Elmiron lawsuits as outlined above, today is the best time to make your claim.

client contacts lawyer about Elmiron lawsuit

Where do I go from here?

Discuss the merits of your case with our top Elmiron lawsuit lawyers now.

Also, you should start saving every document your representing attorneys may need as evidence. That includes any proofs of purchase and receipts of Elmiron. Our lawyers will tell you much more when you contact us. 

Top Reasons to Choose Lawsuit Help Desk

We believe in providing honest and direct access to the top mass torts attorneys. We are not a third party middleman.

Call now and let us give you  immediate access to top 1%, nationally renowned mass torts attorneys, with proven expertise in Elmiron litigation. 

Lawsuit Help Desk prides itself on being a resource for people seeking simple and honest legal assistance.

Call us now and start a hassle-free process with us.

We won’t spam you with unsolicited emails, as we only send informative updates on case status and research.

No robocalls either! We are here to help, not badger, you and your family.

Our active team of mass torts lawyers and litigators will given you full attention and honesty.

Lawsuit Help Desk founder, Cameron Tousi, has decades of experience and comprehensive legal knowledge that made Lawsuit Help Desk a trusted name in the legal industry.

If you call us now, you can ask for Cameron to speak with you directly! 

Monthly Status Updates: Elmiron Lawsuits

February 20, 2023

The Elmiron class action lawsuit has expanded further as of February 20, 2023, with 31 additional cases involving vision loss being filed or transferred to the MDL. The total number of pending cases in the Elmiron MDL has now reached 1,872. In three months’ time, the first bellwether test trial is scheduled to commence, and many believe that Janssen may soon settle substantial portions of these cases.

February 16, 2023

An explanation of Fundus Autofluorescence (FAF) testing and its impact on Elmiron lawsuits was provided. FAF testing is a diagnostic tool utilized in ophthalmology to evaluate the retina’s health, which is the eye’s light-sensitive tissue at the back. Using a special camera, FAF testing captures the retina’s natural fluorescence in response to light, allowing doctors to detect abnormalities and track the progression of certain eye conditions.

In Elmiron lawsuits, FAF testing has been used to confirm retinal damage and visual disturbances resulting from Elmiron. Ophthalmologists employ FAF testing to monitor any related eye conditions and determine the extent of damage caused by the drug. In addition, Elmiron lawyers are utilizing FAF testing to demonstrate that the patients’ injuries were caused by Elmiron and not some other factor.

February 13, 2023

On February 13, 2023, a new Elmiron lawsuit was transferred into the MDL, specifically Padelford v. Janssen Pharmaceuticals Inc., et al. (2:23-cv-265). The plaintiff, a resident of Izard County, Arkansas, took Elmiron daily for interstitial cystitis from 2001 to 2008 and claimed that neither she nor her doctor were warned about the risk of eye injury from Elmiron. She accusesthat her long-term use of the drug caused serious damage to her eyes, resulting in impaired vision. The Complaint sets out six causes of action, with the primary claim being failure to warn.

February 1, 2023

There were 1,841 Elmiron lawsuits in the MDL, with an estimated 175 cases in state courts. With an upcoming trial that Janssen wishes to avoid in March, settlement calculations have been made, with an average Elmiron settlement of $400,000 resulting in just over $800 million in settlements. While this figure may seem significant, it is relatively insignificant for Janssen/J&J, who had likely projected many more plaintiffs in this case.

January 29, 2023

The first bellwether trial in the Elmiron class action MDL, specifically the Windham v. Janssen Pharmaceuticals, et al. (20-cv-14670) case, is set to commence in two months. The defendants have filed pretrial motions, including a motion for summary judgment and a motion to exclude certain expert testimony, which have been fully briefed, and Judge Martinotti is expected to rule on them together in the next few weeks. Despite being ready for trial, it is unlikely that the case will proceed to trial as Janssen is too smart to risk a large verdict that would raise awareness of the connection between Elmiron and vision-related injuries.

On January 17, 2023, it was reported that only three new Elmiron vision damage lawsuits were added to the class action MDL in the past month, bringing the total number of cases to 1,841. This could suggest that the litigation is entering a new phase where only a small number of cases will be filed each month. However, with the first bellwether trial only two months away, it is predicted that Janssen will settle rather than risk a large verdict that could increase awareness of the link between Elmiron and vision-related injuries.

While it is unfortunate that many people with strong claims may not be aware of their eligibility to file a lawsuit, the lower number of cases is a positive development for those who already have lawsuits pending. This is because Janssen may be more inclined to pay higher settlement amounts without negatively impacting shareholders. As a result, there is a possibility of faster settlements and larger payouts for existing Elmiron lawsuits.

January 11, 2023

On January 11, 2023, it was announced that updated medical records are needed from clients to ensure their Plaintiff Fact Sheet is current. Clients who have recently visited their ophthalmologist or retina specialist are encouraged to share this information.

In spite of a significant slowdown in the volume of Elmiron vision damage lawsuits in 2022, new cases are still being filed. One such case is Keys v. Janssen Pharmaceuticals, Inc., et al. (2:22-cv-07487), filed by Shirley Keys, an Arkansas woman who had taken Elmiron for many years to treat her bladder condition. According to the lawsuit, Keys developed pigmentary maculopathy (a unique eye disease caused by Elmiron), which resulted in blurred and distorted vision. This case was filed directly in the Elmiron class action MDL in the District of New Jersey on January 8, 2023.

December 30, 2022

An update as of December 30, 2022 indicates that the trial date for the mass tort case involving Elmiron is still scheduled for March 2023, despite several previous postponements. Although the rate of new cases being added to the Elmiron MDL has decreased in 2022, the lawsuits are being consolidated in the US District Court for the District of New Jersey. The first bellwether trial for the Elmiron MDL is slated to begin on January 30, 2023.

As of December 2022, numerous Elmiron lawsuits have been filed against the drug’s manufacturer, Janssen Pharmaceuticals. These legal claims accuse Janssen of failing to adequately warn users about the health risks associated with long-term use of Elmiron. Plaintiffs in these cases cite vision problems and other ocular issues as major side effects. Additionally, there are claims that Janssen was aware of a growing body of evidence linking Elmiron to pigmentary maculopathy—a condition that can cause vision impairment or blindness—but they did not update their warning label accordingly. 

MDL update

Hundreds of plaintiffs have come forward with accusations of harm related to Elmiron usage. In order to consolidate and streamline pre-trial proceedings, the U.S. Judicial Panel on Multidistrict Litigation (MDL) appointed Judge Brian R. Martinotti of the U.S. District Court for the District of New Jersey to preside over all federally filed Elmiron lawsuits in October 2020. The MDL panel also ordered that all pretrial proceedings, including discovery and motion practice, should be coordinated under the oversight of Judge Martinotti’s court, allowing for more efficient handling of these claims.

November 17, 2022

There is an update on the Elmiron class action lawsuit. At the beginning of the year, the MDL saw a surge in new cases, with over 200 being transferred each month. This caused the number of pending cases in the Elmiron class action MDL to double from 700 to 1,700 in the first half of 2022. However, starting around July, the influx of new lawsuits has drastically decreased, with only ten cases being added to the MDL in the past month. The current number of pending cases is 1,784, indicating that only 59 new Elmiron lawsuits have been filed since July.

November 7, 2022

It was announced that the first bellwether test trial for the Elmiron class action lawsuit, which was scheduled to begin in January 2023, has been delayed. This trial is expected to be significant in determining the course of action for these cases towards a global settlement. However, the Elmiron MDL judge has issued an Order moving the trial to March 27, 2023, without providing any explanation for the postponement. It is important to note that two additional test Elmiron bellwether trials are also scheduled to take place after this one.

October 28, 2022

The opening bellwether trial, which is highly anticipated in determining the course of action for the Elmiron vision damage MDL towards a global settlement, was originally set for January 2023. However, earlier this week, the MDL Judge postponed the trial date to March 27, 2023. The reason for the postponement is unclear as there is no explanation in the Order.

October 22, 2022

The Elmiron class action MDL now has 1,784 lawsuits pending, with only ten new cases being added over the past month. This marks the third consecutive month of minimal new case growth, compared to earlier in the year when an average of over 100 new filings were made each month.

October 12, 2022

The first Elmiron lawsuit, Windham v. Jansen, et al. – 2:20-md-2973, is scheduled to begin on January 30, 2023. Recently, the MDL Judge Martinotti issued a Case Management Order with all the critical pre-trial dates and deadlines. All briefings on expert witness challenges under Daubert will conclude by November 10, 2022. Both sides must submit their witness and exhibit lists for trial on December 2, 2022, and objections must be filed by January 6, 2023. The pre-trial motions hearing will be held on January 16, 2023.

September 16, 2022

The Elmiron class action MDL has slowed down significantly from its peak a few months ago when 150 to 200 new lawsuits were being added each month. In the past month, from August 15th to September 15th, only 34 new cases were added to the MDL, bringing the total number of pending cases to 1,774. 

Despite the slowdown, the first bellwether test trial is still scheduled to take place in January, followed by two more trials in March and May. Elmiron lawyers believe there are still many victims out there who have not yet made the connection between their eye injury and Elmiron use.

September 2, 2022

During the monthly status conference in the Elmiron MDL, Judge Martinotti confirmed that the Windham case will be the first bellwether test trial, followed by a new bellwether case selected by the defense, and the Manning case will be the third. 

Only 15 new lawsuits were added to the MDL in the last month, which is a significant decrease compared to the average of 60 per month since March. As of now, there are 1,740 claims in the class action lawsuit with an additional 169 Elmiron lawsuits pending in New Jersey state courts.

As of August 2022, the IC drug market is predicted to grow by more than 50% in the next six years, with an increase of 6.6% this year.

In the past month, only 15 new cases have been added to the Elmiron MDL, bringing the total number of pending cases to 1,740 as of August 15. An additional 169 cases are awaiting resolution in New Jersey state courts.

MDL update

Following the most recent monthly status conference, the Elmiron MDL Judge issued a housekeeping Order on August 16, confirming that the first bellwether trial will be the Windham case, while Manning will be the third test trial next year. The defense will select a new bellwether case by the end of the month, which will be the second case to go to trial.

July turned out to be an uneventful month for the Elmiron class action lawsuit. Although record-high numbers of cases were previously being transferred into the MDL, no new cases were added after July 7, 2022. Judge Martinotti held a status conference on July 13, 2022, resulting in an order regarding appointments to the Plaintiffs’ Steering Committee. However, no additional docket entries have been made since then. The smaller size of the Elmiron lawsuit might bode well for settlement amounts for victims.


A recent update on the Elmiron class action lawsuit reveals an increase in activity during the summer months. From June 15 to July 15, a total of 365 new plaintiffs with Elmiron vision damage lawsuits were transferred into the Elmiron MDL, bringing the current total of pending plaintiffs to 1,725. This surge marks the largest increase in new cases since the start of the Elmiron MDL and the most significant percentage increase for any mass tort during the same period. It is expected that this trend will continue until the bellwether trials begin in January.

July 2022 marks an important milestone in the ongoing Elmiron lawsuits. The FDA has officially declared that Elmiron is not safe for long-term use, and many patients are now filing claims against pharmaceutical companies Janssen and Teva for their accused negligence in not warning about side effects of the drug. Hundreds of individuals have filed dozens of class action lawsuits in state and federal courts across the country, citing serious health consequences such as vision loss, maculopathy, bladder pain syndrome, cognitive impairment, and other urinary problems attributed to taking Elmiron. As the number of plaintiffs grows each month, it’s likely that more may join before July 2022 arrives.

Evidence gathering 

Several major law firms have taken on these cases and are actively pursuing claims against the pharmaceutical companies. As part of the legal strategy, they are gathering evidence and researching medical literature to prove that Elmiron can be harmful in the long term. They also plan to seek punitive damages from Janssen and Teva as a means of holding them accountable for any harm caused by their product. 

As July 2022 approaches, it’s likely that there will be more progress made on these lawsuits. More plaintiffs may join, more facts and research will come out about Elmiron’s dangers, and the courts may finally begin to grant class-action status for some cases. This could mean a major payout for those affected by taking Elmiron for an extended period of time. 

June 7, 2022

It was announced that the first Elmiron eye damage lawsuit will go to trial in January 2023, which has been rescheduled to March 2023. The defense lawyers have selected Maria Windham’s case to be the first trial, indicating that it is a strong case for the defendants. However, the plaintiff’s attorneys are confident that the case is winnable. While Louisiana law is typically not favorable to victims, our attorneys believe that every Elmiron lawsuit has a strong chance of success at trial, including Windham’s case.

June 3, 2022

On June 3, 2022, an update was issued regarding the Elmiron lawsuit. Following the selection of the first three bellwether IC medication trials, the judge in the Elmiron MDL issued a Case Management Order that revised the scheduling deadlines for pretrial discovery and motions in the test cases.

According to the new order, pre-trial discovery for all three Elmiron lawsuits going to trial will be completed by September 9, 2022, and dispositive motions will be due by September 20, 2022. The first bellwether trial for Elmiron will be held in January 2023, followed by the second trial in March and the third in May of the same year.

Elmiron eye damage class action is expected  to have more plaintiffs, as many people with eye damage may not have linked their injuries to Elmiron. However, in the past month, there has been a significant increase in new lawsuits added to the MDL class action. A total of 326 new Elmiron eye damage lawsuits were added, marking the most significant monthly increase in new Elmiron lawsuits to date. This increase may be a sign of heightened awareness and is also one of the largest increases in new cases among all mass tort MDLs in the country.

May 10, 2022

On May 10, 2022, the judge overseeing the Elmiron class action announced the three cases chosen for the bellwether trials: Manning (21-cv-11942), Broussard (21-cv-2028), and Windham (20-cv-14670).

One of the plaintiffs, Julia Manning, is from Georgia and was selected by the plaintiffs’ team. She took Elmiron from 2008 to 2014 and sustained damage to both of her eyes. Opal Broussard, a Louisiana resident who claims she suffered “a loss of vision and a diagnosis of macular degeneration” after taking Elmiron, was chosen by the defense.

Maria Windham, the third plaintiff, was chosen by the MDL Judge, but it was also a case nominated by the defense. Windham, who is 67 years old and from Louisiana, accuses that she developed pigmentary maculopathy after using Elmiron for two years. Typically, in a class action lawsuit, any case the defendant chooses would result in a defense verdict. However, Elmiron lawyers believe that the cases in this litigation are strong enough to have a chance of winning in any case that goes to trial.

May 5, 2022

On May 5, 2022, it was reported that more than 900 individuals have joined the Elmiron lawsuit in federal court in New Jersey. However, the growth of this class action has been slower than what many Elmiron lawyers expected. One possible reason for this slow growth is the lack of connection between Elmiron and vision loss among patients and prescribing doctors. While television commercials can increase awareness in class action lawsuits, there are not enough claims for Elmiron attorneys to make a strong investment in marketing vision loss lawsuits on television.

Unfortunately, this lack of awareness means that many eligible plaintiffs may not realize they have a claim. On the other hand, for patients who have brought a claim, the settlement amounts for the Elmiron lawsuit may be higher per person in a mass tort with fewer plaintiffs. This makes it easier for the defendants to resolve the lawsuit without burdening shareholders, which may lead to higher settlement payouts.

April 14, 2022

The monthly status conference for the Elmiron MDL-2973 is scheduled soon. The upcoming conference is expected to discuss various housekeeping issues related to the bellwether selection process of the Elmiron class action lawsuit. Also, a new date for the science day, which has been rescheduled multiple times, may be set during the conference.

April 1, 2022

In March’s Monthly Status Conference, the Elmiron class action judge issued Case Management Order No. 27, which updated the litigation’s status. The order revealed that 803 product liability lawsuits have been filed against Elmiron, with 712 in federal courts, 91 in New Jersey state courts, and an unknown number in Pennsylvania state court. Moreover, the judge agreed to reschedule the science day, which has been postponed for the third time.

In the aftermath of the March Monthly Status Conference, the judge overseeing the Elmiron MDL issued Case Management Order (CMO) No. 27, which provides an updated status of the litigation as of March 9, 2022. One of the primary concerns of the court is the number of Elmiron lawsuits that have been filed to date, which currently stands at 803 product liability lawsuits. Of these, 712 cases are part of the federal Elmiron class action lawsuit, while the remaining 91 lawsuits are pending in New Jersey state court. Additionally, the highly anticipated “Elmiron Science Day” has been rescheduled for the third time, but a new proposed date or time frame has not been announced yet.

March 17, 2022

The judge in the Elmiron MDL released several Case Management Orders that dealt with procedural issues and established a plan for the litigation in the coming months.

During the upcoming monthly status conference, Judge Martinotti is expected to finalize the protocol for selecting the first bellwether cases. Fact discovery on the group of bellwether candidate cases is set to end by the end of the month. The initial set of bellwether trial cases will be chosen by April 8, 2022. 

Bellwether trials

The Elmiron MDL judge issued several Case Management Orders last week, setting the groundwork for the next phase of litigation and the first bellwether trials in January. The parties were directed to submit a joint proposal for selecting the first bellwether cases, and fact discovery on the pool of bellwether candidates will be completed by the end of the month. The initial bellwether trial cases will be chosen by April 8. The long-awaited “science day” is scheduled for March 25, and a mandatory Case & Claim Data Form (“CCDF”) has been approved, which all plaintiffs must submit within 30 days.

Currently, there are 783 lawsuits pending in the Elmiron MDL class action lawsuits, which encompass all Elmiron suits filed in federal court.

February 22, 2022

A single judge in Bergen County will preside over all Elmiron vision loss lawsuits that have been filed in New Jersey state courts, according to a directive from the state’s highest court. This consolidation resembles the multidistrict litigation (MDL) procedure used in federal courts. More than 800 Elmiron lawsuits have already been merged in the Elmiron MDL-2973 in federal courts.

New cases

More than 800 Elmiron lawsuits have been consolidated in federal court, although there are also those consolidated in the New Jersey Supreme Court. The court ordered that all Elmiron lawsuits in the state court system will be consolidated before a single judge in Bergen County. In New Jersey, this is comparable to an MDL. Hence, the total number of Elmiron lawsuits will inevitably increase. Currently, there are 736 Elmiron lawsuits in the MDL and the consolidation of the New Jersey cases will occur in the same location as Janssen Pharmaceuticals, which is the defendant in the lawsuits.


January 13, 2022

A case management conference was held in the Elmiron class action lawsuit. Despite this, no significant developments were reported. The Science Day, where expert witnesses would educate the judge on the litigation issues, was postponed to March 23, 2022. In early 2022, Judge Martinotti will conduct a “science day,” where lawyers from both sides will present their medical and scientific evidence to the court. The first bellwether trials for Elmiron litigation are scheduled for March 2023, but due to the strong scientific evidence connecting Elmiron to pigmentary maculopathy, a global settlement may be reached before a bellwether trial occurs.

January 7, 2022

The number of Elmiron class action lawsuits has increased to 679, compared to 622 in November and 580 in October. Additionally, 80 lawsuits have been filed in state courts in New Jersey and Pennsylvania. The number of lawsuits related to Elmiron and vision side effects is expected to exceed 1,000 in 2022 as awareness of the connection between the two grows, according to Elmiron lawyers.

Under the jurisdiction of Judge Brian Martinotti, the Elmiron MDL (In Re: Elmiron (Pentosan Polysulfate Sodium) Prod. Liab. Litigation, MDL 2973) was established in the U.S. District Court for New Jersey. As of December 15, 2021, nearly 800 Elmiron lawsuits are pending in the MDL, with Judge Martinotti expediting pre-trial discovery. However, the litigation will likely slow down during the Christmas season, but will continue at full capacity in January.

It is important to note that drugs such as Beovu can also cause blindness, and Elmiron’s label change in June 2020 highlights the need for a black box warning. 

December 14, 2021

Judge Brian Martinotti of the District of New Jersey held a case management conference to address logistics of document discovery from Janssen Pharmaceuticals and proposed dates for rescheduling the Elmiron “Science Day” in the Elmiron MDL class action lawsuit.

December 5, 2021

The Judicial Panel on Multidistrict Litigation established a new MDL class action to consolidate all Elmiron lawsuits in federal courts. The Elmiron litigation is underway, mostly with discovery against Janssen and Teva, as lawyers prepare for the first bellwether trial in January 2023. Judge Martinotti has ordered the parties to prepare a bellwether test trial plan, with three trial dates now set.

While the trial of the first eye injury case is still almost a year away, our Elmiron lawsuit attorneys predict that a global settlement will occur before a single Elmiron lawsuit goes to trial, given the strength of the plaintiffs’ cases.

November 1, 2021

Judge Martinotti denied the defendant’s motion to modify Management Order #1 was dismissed. The motion basically asserts that a manufacturing problem was at the core issue of the allegations. Nevertheless, the judge ruled that this motion premature. The merits of the case is best determined during trial.

The results of the study indicated that Elmiron exposure was linked to a higher risk of maculopathy, but more research is needed. This study provides more evidence in support of plaintiffs’ claims for damages due to their use of Elmiron. 

Update October 22, 2021: Science Day Postponed. Judge Martinotti had initially scheduled “Science Day” to enable lawyers from both sides in the Elmiron class action lawsuit to provide an overview of the medical and scientific issues relevant to the case. However, this has now been postponed to a later date yet to be determined.

October 1, 2021

Recent research continues to support arguments made by attorneys representing those filing suit against Elmiron for resulting eye injuries and blindness. A Northwestern University study assessed the presence of Elmiron-related maculopathy by looking at medical records from 131 patients, 40 of whom underwent imaging while 91 went through fundus examinations. The results revealed an increased risk of maculopathy connected to Elmiron exposure, though further research is necessary. This study provides additional evidence that bolsters plaintiffs’ claims for damages due to their use of this medication. 

News & Articles

Elmiron Exposed: The Unseen Eye Disaster Tied to Your Prescription, and the Unheard Voices of the Victims

Elmiron Exposed: The Unseen Eye Disaster Tied to Your Prescription, and the Unheard Voices of the Victims

Section I: Elmiron: The Miracle and The Mirage

In the labyrinth of modern pharmaceuticals, Elmiron stands out as an enigma. Marketed as a miracle drug for the painful bladder condition known as interstitial cystitis, its shadowy side-effect has been obfuscating the vision of those who consume it. This piece unravels the complex web of studies linking Elmiron to unexpected eye disorders, while delving into the silenced narratives of its victims. The aim is to unmask the unseen disaster attached to your prescription, and amplify the unheard voices caught in its wake.

Elmiron, the only FDA-approved oral medication for interstitial cystitis, brought hope to countless people suffering from this chronic pain condition. It was hailed as a miracle, a beacon of relief in a sea of discomfort. However, beneath this promising facade, a mirage may be exerting a sinister influence. The alleged side effect? A unique form of vision impairment that could turn the miracle into a nightmare.

Section II: The Clinical Connection: Elmiron and Eye Disorders

Emerging studies have started to highlight a potential correlation between long-term Elmiron usage and a distinct pattern of retinal damage. A groundbreaking study by the Emory Eye Center in 2018 flagged this unexpected connection. Of the 140 patients surveyed, about one-quarter showed clear signs of this specific eye disorder. This alarming revelation sparked a flurry of research that stoked the flames of suspicion. The Elmiron-eye disorder puzzle was beginning to come together, but the picture was far from complete.

Section III: Personal Narratives: The Unseen Victims of Elmiron

Across the nation, the voices of those allegedly impacted by Elmiron's side effects have begun to rise. Meet Jennifer Smith, a vibrant artist whose world blurred overnight. She reported, "I woke up one morning and everything was covered in a fog. It's like an artist's worst nightmare." No longer able to capture the world in her beautiful brush strokes, she was left questioning- did Elmiron play a part in dimming her colorful life?

Next, there's Michael Thompson, a retired firefighter who relied on Elmiron for years. He recounts, "I thought I was just getting old. But then I realized, my vision was clouding over a lot faster than my peers." Is it just age, or has Elmiron clouded more than just his immediate sight?

The stories of Jennifer Smith and Michael Thompson, who we met earlier, are but two among a growing chorus. The unseen victims, their lives forever altered, are beginning to step out of the shadows. For them, the nightmare is real, their vision clouded, their lives disrupted. Their personal narratives, poignant and heart-wrenching, serve as a stark reminder of the potential human cost of this alleged disaster.

Section IV: The Silent Aftermath: How Elmiron Continues to Cloud Vision

The wake left by Elmiron is not just a trail of personal misfortunes. It's allegedly painting a larger, more insidious picture.

  • Eye clinics are reportedly seeing an influx of patients with similar symptoms: declining vision and a unique pattern of retinal damage.
  • Ophthalmologists appear to be connecting the dots, with growing concerns that, allegedly, Elmiron might be the common factor.
  • Medical journals have begun discussing this potential link, raising the question: are these isolated incidents or the tip of an iceberg?

The aftermath of the alleged Elmiron crisis paints a grim picture. Eye clinics are reportedly seeing an influx of patients with similar symptoms. Ophthalmologists are connecting the dots, their concerns growing as Elmiron becomes a common denominator. Medical journals are abuzz with discussions about the correlation between Elmiron and these unique eye disorders. It seems the aftermath is silent but increasingly devastating.

Section V: The Future of Elmiron: Confronting the Crisis and Seeking Solutions

The future of Elmiron is shrouded in uncertainty.

  • Will the alleged potential side effects be substantiated through more rigorous studies?
  • Will patients and physicians be warned about the possible risks associated with prolonged use?
  • Will regulatory bodies like the FDA step in to ensure this alleged crisis is addressed?

These are just a few questions that surround Elmiron's future. But amidst these questions, one thing is certain: the voices of its alleged victims and concerned physicians will continue to rise, seeking answers, justice, and more importantly, solutions.

As the Elmiron puzzle continues to unravel, its future is shrouded in questions. Will further research validate these alleged side effects? Will the healthcare and pharmaceutical industry heed these warnings and take action? Will regulatory bodies step in to protect the patients? Amidst the uncertainty, one thing is clear: the voices of the alleged victims are getting louder, clamoring for justice and solutions. The future of Elmiron is in our hands, and it is high time we confront this crisis head-on.'s mission is to restore justice by finding every mass tort victim leading litigation counsel. Our services are free! We're also the leading information portal for people who have been injured from mass torts. We'd love to hear from you!

PAID ATTORNEY ADVERTISEMENT: This Website is a group advertisement. It is not a lawyer referral service. is owned and operated by Awon Holdings LLC and is not a law firm. We connect people to legal service and there is no charge to be connected with an attorney. You are under no obligation to retain any services of those connected through our website. We try our best to keep things fair and balanced to help you make the best choice for you. This information does not constitute legal or medical advice and it should not be relied upon as such. Results are not guaranteed and past performance is not an indication of future success. Always consult with your doctor before modifying your medication or regular medical regimen.

Copyright © 2023 - All Rights Reserved